Global Asthma Inhalation Formulation Market Research Report 2024

Publication ID:

PB509246260

Publication Date:

September 18, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Asthma inhalation formulations are specialized medications designed to deliver drugs directly to the lungs, offering rapid relief and control of asthma symptoms. These formulations typically include bronchodilators, which relax the muscles around the airways, and corticosteroids, which reduce inflammation. Inhalation allows the medication to act quickly and directly on the affected areas with fewer systemic side effects compared to oral or intravenous treatments. Common inhalation devices include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, each tailored to different patient needs and preferences. Advances in inhalation technology, such as the development of breath-actuated inhalers and combination inhalers containing multiple drugs, have improved the management of asthma by enhancing drug delivery and patient adherence.
The global Asthma Inhalation Formulation market was valued at US$ 12150 million in 2023 and is anticipated to reach US$ 18930 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.
North American market for Asthma Inhalation Formulation is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Asthma Inhalation Formulation is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Asthma Inhalation Formulation include Recipharm AB, GSK, AstraZeneca, Novartis, Teva Respiratory, Boehringer Ingelheim International, Cipla, Merck, Lupin, Perrigo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Asthma Inhalation Formulation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Asthma Inhalation Formulation.
The Asthma Inhalation Formulation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Asthma Inhalation Formulation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Asthma Inhalation Formulation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Recipharm AB
GSK
AstraZeneca
Novartis
Teva Respiratory
Boehringer Ingelheim International
Cipla
Merck
Lupin
Perrigo
Viatris
Organon Group
Segment by Type
Corticosteroids
Bronchodilators
Segment by Application
Hospitals
Specialty Clinics
Retail Pharmacy Chains
Online Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Asthma Inhalation Formulation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Asthma Inhalation Formulation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Asthma Inhalation Formulation Market Overview
1.1 Product Definition
1.2 Asthma Inhalation Formulation by Type
1.2.1 Global Asthma Inhalation Formulation Market Value Comparison by Type (2024-2030)
1.2.2 Corticosteroids
1.2.3 Bronchodilators
1.3 Asthma Inhalation Formulation by Application
1.3.1 Global Asthma Inhalation Formulation Market Value by Application (2024-2030)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Retail Pharmacy Chains
1.3.5 Online Pharmacies
1.3.6 Other
1.4 Global Asthma Inhalation Formulation Market Size Estimates and Forecasts
1.4.1 Global Asthma Inhalation Formulation Revenue 2019-2030
1.4.2 Global Asthma Inhalation Formulation Sales 2019-2030
1.4.3 Global Asthma Inhalation Formulation Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Asthma Inhalation Formulation Market Competition by Manufacturers
2.1 Global Asthma Inhalation Formulation Sales Market Share by Manufacturers (2019-2024)
2.2 Global Asthma Inhalation Formulation Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Asthma Inhalation Formulation Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Asthma Inhalation Formulation, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Asthma Inhalation Formulation, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Asthma Inhalation Formulation, Product Type & Application
2.7 Global Key Manufacturers of Asthma Inhalation Formulation, Date of Enter into This Industry
2.8 Global Asthma Inhalation Formulation Market Competitive Situation and Trends
2.8.1 Global Asthma Inhalation Formulation Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Asthma Inhalation Formulation Players Market Share by Revenue
2.8.3 Global Asthma Inhalation Formulation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Asthma Inhalation Formulation Market Scenario by Region
3.1 Global Asthma Inhalation Formulation Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Asthma Inhalation Formulation Sales by Region: 2019-2030
3.2.1 Global Asthma Inhalation Formulation Sales by Region: 2019-2024
3.2.2 Global Asthma Inhalation Formulation Sales by Region: 2025-2030
3.3 Global Asthma Inhalation Formulation Revenue by Region: 2019-2030
3.3.1 Global Asthma Inhalation Formulation Revenue by Region: 2019-2024
3.3.2 Global Asthma Inhalation Formulation Revenue by Region: 2025-2030
3.4 North America Asthma Inhalation Formulation Market Facts & Figures by Country
3.4.1 North America Asthma Inhalation Formulation Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Asthma Inhalation Formulation Sales by Country (2019-2030)
3.4.3 North America Asthma Inhalation Formulation Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Asthma Inhalation Formulation Market Facts & Figures by Country
3.5.1 Europe Asthma Inhalation Formulation Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Asthma Inhalation Formulation Sales by Country (2019-2030)
3.5.3 Europe Asthma Inhalation Formulation Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Asthma Inhalation Formulation Market Facts & Figures by Region
3.6.1 Asia Pacific Asthma Inhalation Formulation Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Asthma Inhalation Formulation Sales by Region (2019-2030)
3.6.3 Asia Pacific Asthma Inhalation Formulation Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Asthma Inhalation Formulation Market Facts & Figures by Country
3.7.1 Latin America Asthma Inhalation Formulation Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Asthma Inhalation Formulation Sales by Country (2019-2030)
3.7.3 Latin America Asthma Inhalation Formulation Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Asthma Inhalation Formulation Market Facts & Figures by Country
3.8.1 Middle East and Africa Asthma Inhalation Formulation Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Asthma Inhalation Formulation Sales by Country (2019-2030)
3.8.3 Middle East and Africa Asthma Inhalation Formulation Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Asthma Inhalation Formulation Sales by Type (2019-2030)
4.1.1 Global Asthma Inhalation Formulation Sales by Type (2019-2024)
4.1.2 Global Asthma Inhalation Formulation Sales by Type (2025-2030)
4.1.3 Global Asthma Inhalation Formulation Sales Market Share by Type (2019-2030)
4.2 Global Asthma Inhalation Formulation Revenue by Type (2019-2030)
4.2.1 Global Asthma Inhalation Formulation Revenue by Type (2019-2024)
4.2.2 Global Asthma Inhalation Formulation Revenue by Type (2025-2030)
4.2.3 Global Asthma Inhalation Formulation Revenue Market Share by Type (2019-2030)
4.3 Global Asthma Inhalation Formulation Price by Type (2019-2030)
5 Segment by Application
5.1 Global Asthma Inhalation Formulation Sales by Application (2019-2030)
5.1.1 Global Asthma Inhalation Formulation Sales by Application (2019-2024)
5.1.2 Global Asthma Inhalation Formulation Sales by Application (2025-2030)
5.1.3 Global Asthma Inhalation Formulation Sales Market Share by Application (2019-2030)
5.2 Global Asthma Inhalation Formulation Revenue by Application (2019-2030)
5.2.1 Global Asthma Inhalation Formulation Revenue by Application (2019-2024)
5.2.2 Global Asthma Inhalation Formulation Revenue by Application (2025-2030)
5.2.3 Global Asthma Inhalation Formulation Revenue Market Share by Application (2019-2030)
5.3 Global Asthma Inhalation Formulation Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Recipharm AB
6.1.1 Recipharm AB Company Information
6.1.2 Recipharm AB Description and Business Overview
6.1.3 Recipharm AB Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Recipharm AB Asthma Inhalation Formulation Product Portfolio
6.1.5 Recipharm AB Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Asthma Inhalation Formulation Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Asthma Inhalation Formulation Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Asthma Inhalation Formulation Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Teva Respiratory
6.5.1 Teva Respiratory Company Information
6.5.2 Teva Respiratory Description and Business Overview
6.5.3 Teva Respiratory Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Teva Respiratory Asthma Inhalation Formulation Product Portfolio
6.5.5 Teva Respiratory Recent Developments/Updates
6.6 Boehringer Ingelheim International
6.6.1 Boehringer Ingelheim International Company Information
6.6.2 Boehringer Ingelheim International Description and Business Overview
6.6.3 Boehringer Ingelheim International Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim International Asthma Inhalation Formulation Product Portfolio
6.6.5 Boehringer Ingelheim International Recent Developments/Updates
6.7 Cipla
6.7.1 Cipla Company Information
6.7.2 Cipla Description and Business Overview
6.7.3 Cipla Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Cipla Asthma Inhalation Formulation Product Portfolio
6.7.5 Cipla Recent Developments/Updates
6.8 Merck
6.8.1 Merck Company Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Asthma Inhalation Formulation Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 Lupin
6.9.1 Lupin Company Information
6.9.2 Lupin Description and Business Overview
6.9.3 Lupin Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Lupin Asthma Inhalation Formulation Product Portfolio
6.9.5 Lupin Recent Developments/Updates
6.10 Perrigo
6.10.1 Perrigo Company Information
6.10.2 Perrigo Description and Business Overview
6.10.3 Perrigo Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Perrigo Asthma Inhalation Formulation Product Portfolio
6.10.5 Perrigo Recent Developments/Updates
6.11 Viatris
6.11.1 Viatris Company Information
6.11.2 Viatris Description and Business Overview
6.11.3 Viatris Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Viatris Asthma Inhalation Formulation Product Portfolio
6.11.5 Viatris Recent Developments/Updates
6.12 Organon Group
6.12.1 Organon Group Company Information
6.12.2 Organon Group Description and Business Overview
6.12.3 Organon Group Asthma Inhalation Formulation Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Organon Group Asthma Inhalation Formulation Product Portfolio
6.12.5 Organon Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Asthma Inhalation Formulation Industry Chain Analysis
7.2 Asthma Inhalation Formulation Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Asthma Inhalation Formulation Production Mode & Process
7.4 Asthma Inhalation Formulation Sales and Marketing
7.4.1 Asthma Inhalation Formulation Sales Channels
7.4.2 Asthma Inhalation Formulation Distributors
7.5 Asthma Inhalation Formulation Customers
8 Asthma Inhalation Formulation Market Dynamics
8.1 Asthma Inhalation Formulation Industry Trends
8.2 Asthma Inhalation Formulation Market Drivers
8.3 Asthma Inhalation Formulation Market Challenges
8.4 Asthma Inhalation Formulation Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Recipharm AB
GSK
AstraZeneca
Novartis
Teva Respiratory
Boehringer Ingelheim International
Cipla
Merck
Lupin
Perrigo
Viatris
Organon Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂